BoomRay

BoomRay was incubated and established in 2018 with the support of WuXi AppTec to assist the Su Nan Institute of Molecular Engineering at Peking University. The company fully utilizes foundational research achievements from Peking University and is committed to building a next-generation platform for the research, production, and clinical application of radiopharmaceuticals. All products currently in the company’s pipeline are self-developed, with global intellectual property rights. BoomRay’s R&D portfolio includes multiple First-in-Class (FIC) / Best-in-Class (BIC) radionuclide conjugates and neutron capture therapy drugs, covering diagnostic and therapeutic products for various indications, including head and neck tumors, brain tumors, and more.